Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
Elamipretide (SS-31)
Mitochondria-targeted tetrapeptide that binds cardiolipin
View Elamipretide (SS-31)| Property | MOTS-c | Elamipretide (SS-31) |
|---|---|---|
| Class | Mitochondrial-derived peptide | Mitochondria-targeted peptide |
| Research category | metabolism and longevity | mitochondrial myopathies and bioenergetics |
| Evidence level | Low | Moderate |
| Overall status | Not approved — preclinical | Investigational; FDA accelerated approval for Barth syndrome (2025) |
| FDA | Not approved | Accelerated approval (Rx) — Barth syndrome |
| EMA | Not approved | Not approved |
| WADA | Prohibited — check current list | Check current list |
| Mechanism studied | MOTS-c → Folate–methionine pathway → AICAR / AMPK → Glucose uptake | SS-31 → Inner mitochondrial membrane → Cardiolipin stabilisation → ATP production & ROS |
| Molecular weight | 2,174.6 g/mol | 639.8 g/mol |
| Sizes in stock | 10mg, 40mg | 10mg, 50mg |
Where the research overlaps
Both compounds are studied within Longevity & Cellular Health research. MOTS-c is classed as mitochondrial-derived peptide, while Elamipretide (SS-31) is mitochondria-targeted peptide. Evidence is rated low for MOTS-c and moderate for Elamipretide (SS-31).
For a full write-up, read Mitochondrial Peptides: MOTS-c, Humanin and SS-31.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.